PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak
- Conditions
- Postherpetic Neuralgia
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00506610
- Locations
- πΊπΈ
Bradenton Research Center, Bradenton, Florida, United States
πΊπΈAnchor Research Center, Naples, Florida, United States
πΊπΈSuncoast Clinical Research, New Port Richey, Florida, United States
Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 684
- Registration Number
- NCT00503139
- Locations
- π―π΅
Hokkaido University Hospital, Sapporo, Japan
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 314
- Registration Number
- NCT00503529
- Locations
- π΅π±
Hospital in Debica - Zespol Opieki Zdrowotnej w Debicy, Debica, Poland
π΅π±Szpital Jana Pawla II (The John Paul II Hospital) Oddzial Neuroinfekcji, Krakow, Poland
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 229
- Registration Number
- NCT00502242
- Locations
- πΏπ¦
Pfizer Investigational Site, Cape Town, Western Cape, South Africa
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1053
- Registration Number
- NCT00500266
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Biological: ACC-001 + QS-21Biological: QS-21Biological: ACC-001
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00498602
- Locations
- πΊπΈ
Banner Alzheimer's Institute, Phoenix, Arizona, United States
πΊπΈBanner Good Samaritan Medical Center, Phoenix, Arizona, United States
πΊπΈBanner Boswell Medical Center, Sun City, Arizona, United States
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
- Conditions
- Candidiasis
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00496197
- Locations
- π°π·
Pfizer Investigational Site, Seoul, Korea, Republic of
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00495677
- Locations
- π©πͺ
Pfizer Investigational Site, Koeln, Germany
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00494091
- Locations
- π°π·
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 13vPnC + TIV
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1185
- Registration Number
- NCT00492557